{"entity":{"id":"symbiotic-lung-01","kind":"trial","name":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","aka":["Symbiotic-Lung-01"],"tldr":"A phase 3 trial testing PF-08634404 in non-small-cell lung cancer, now recruiting.","summary":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07222566, led by Pfizer, and recruiting on the registry. Official title: An interventional phase 3, double-blind, randomised study to evaluate efficacy and safety of PF-08634404 in combination with chemotherapy versus pembrolizumab in combination with chemotherapy in adult participants with locally advanced or metastatic non-small cell lung cancer. Planned enrolment is 1410 participants (estimated). The study started in 2026-01-06 and primary completion is expected in 2029-02-27. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07222566","url":"https://clinicaltrials.gov/study/NCT07222566"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pf-08634404"],"companies":["pfizer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07222566","phase":"3","setting":"An interventional phase 3, double-blind, randomized study to evaluate efficacy and safety of PF-08634404 in combination with chemotherapy versus pembrolizumab in combination with chemotherapy in adult participants with locally advanced or metastatic non-small cell lung cancer","sponsor":"Pfizer","participation":[{"nct":"NCT07222566","source":"https://clinicaltrials.gov/study/NCT07222566","fetchedAt":"2026-10-07T16:55:33.599Z","studySha256":"c640233dac5739031e2e20c043e6d37e2e5586af38e0b85f3ea320e7959be93f","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-25","leadSponsor":"Pfizer","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":1410,"enrolmentType":"ESTIMATED","siteCount":479,"recruitingSiteCount":454,"countries":["Argentina","Australia","Brazil","Canada","China","Czechia","France","Germany","Greece","Hungary","India","Israel","Italy","Japan","Poland","Puerto Rico","Spain","Taiwan","Turkey (Türkiye)","United States"]}],"started":"2026-01-06","startedType":"actual","enrolled":1410,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/symbiotic-lung-01/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"pf-08634404","kind":"drug","name":"PF-08634404","route":"/drugs/pf-08634404/"}],"company":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"}]}}